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Abstract
Introduction: Obstructive sleep apnoea/hypopnea syndrome (OSA) is characterized by obstruction of the upper airway 
during sleep, resulting in repetitive breathing pauses accompanied by oxygen desaturation and arousal from sleep. Among 
the candidate genes affecting the risk of OSA, genes whose polymorphisms influence the development of diseases with 
similar pathogenesis such as OSA could be listed: APOE, genes for leptin and leptin receptor, TNFA1, ADRB2 and ACE (gene 
for angiotensin-converting enzyme). Until now there has been a confirmed relationship between ACE gene polymorphism 
and cardiovascular diseases, but its effect on the incidence of OSA is debatable.
The aim of this study was to investigate the effect of ACE gene insertion/deletion (I/D) polymorphism on the risk of OSA.
Material and methods: Fifty-five patients with confirmed diagnose of OSA and qualified to CPAP therapy entered the study. 
The control group included 50 subjects who did not complain of any sleep related symptoms. Diagnose of OSA was set on 
the basis of full overnight polysomnography together with Epworth Sleepiness Scale according to American Academy of 
Sleep Medicine guidelines. DNA was isolated from peripheral blood leukocytes with Qiagen DNA mini Kit. ACE gene poly-
morphism was determined in genomic DNA using allele specific polymerase chain reaction. Different sizes of PCR products 
were observed on agarose gel electrophoresis.
Results: There were non-significant differences in the frequency of ACE genotypes. However, allele D had significantly lower 
prevalence in the study group than in the control group. (χ² = 4.25 p = 0.04). Moreover, I allele carriers had a threefold 
greater risk of developing OSA (HR = 2.748, 95% CI = 1.029–7.340, p < 0.05).
Conclusions: Analysis of ACE gene polymorphism might be useful to determine the risk of developing OSA in clinically 
predisposed patients.
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Streszczenie
Wstęp: Zespół obturacyjnego bezdechu w czasie snu (obturacyjny bezdech śródsenny, OBŚ) charakteryzuje się pojawianiem 
nawracających epizodów bezdechów lub spłyceń oddychania. Wśród genów kandydatów, wpływających na ryzyko wystąpienia 
OBŚ wymienia się geny, których polimorfizmy wpływają na rozwój chorób o podobnej patogenezie co OBŚ: APOE, geny dla lep-
tyny i receptora leptyny, TNFA1, ADRB2 oraz ACE (gen dla enzymu konwertującego angiotensynę). Dotychczas opisano zależność 
pomiędzy polimorfizmem genu ACE a chorobami sercowo-naczyniowymi, a jego wpływ na zachorowanie na OBŚ jest dyskusyjny. 
Celem pracy było zbadanie wpływu polimorfizmu insercyjno/delecyjnego (I/D) genu ACE na ryzyko zachorowania na OBŚ.
Materiał i metody: Badaniem objęto grupę 55 chorych, którzy zgłaszali się w celu rozpoczęcia terapii CPAP. Grupę kontrolną 
stanowiło 50 osób, które nie zgłaszały zaburzeń snu. Rozpoznanie ustalano na podstawie wyniku polisomnografii (wg kla-
syfikacji AASM) i wartości punktowej Skali Senności Epworth. DNA izolowano z leukocytów krwi obwodowej za pomocą 
zestawu Qiagen DNA mini Kit. Polimorfizm genu ACE oceniano na podstawie długości fragmentów produktów reakcji PCR 
w żelu agarozowym.
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Introduction
Sleep apnoea is defined as the occurrence of 
multiple and recurring episodes of apnoea (bre-
athing arrest) or hypopnoea (shallow breathing) 
during sleep. Obstructive sleep apnoea (OSA) is 
caused by closing of the airway lumen at the level 
of the pharynx despite normal function of the 
respiratory muscles [1–4]. This phenomenon is 
accompanied by hypoxaemia and hypercapnia, with 
resultant episodes of waking up, leading in turn to 
sleep fragmentation and worsening of sleep quality 
[1–4]. Major risk factors for OSA include cervical 
and abdominal obesity as well as structural abnor-
malities of upper airways, which decrease airway 
patency. Most affected patients are men of 45–65 
years of age, many of them obese and overconsu-
ming alcohol, and alternatively cigarette smokers 
[1–11]. Snoring is a sign that is easily detectable 
for persons within the patient’s environment, and 
strongly suggesting OSA [1–4].
Diagnostics of OSA are based on results of 
polysomnographic investigations. Young et al. 
[1, 8] observed the occurrence of obstructive sleep 
apnoea in approximately 2% of women and 4% 
of men when investigating the presence of the 
clinically important syndrome of sleep apnoea 
consisting of apnoea-hypopnea index (AIH) value 
over 5 as assessed by polysomnography and signs 
of somnolence during the daytime. When only 
aberrant results of polysomnographic investigation 
were considered, the incidence of sleep apnoea 
was higher: up to 9% in women and 24% in men. 
Similar results were reported by Kim et al. [9], who 
performed polysomnographic investigations in 
457 persons, of whom AHI ≥ 5 was found in 27% 
of men and 16% of women. These findings, alon-
gside the occurrence of pathological signs during 
the daytime, result in an estimated OSA incidence 
of 4.5% in men and 3.2% in women. In Poland 
a similar study was performed by Pływaczewski et 
al. [10], who investigated 676 subjects. They iden-
tified 76 persons with signs of OSA and marked 
somnolence during the daytime, which represen-
ted approximately 11% of the studied population. 
Wyniki: Nie wykazano statystycznie istotnych różnic w rozkładzie poszczególnych genotypów genu ACE w grupie chorych 
z OBŚ i w grupie kontrolnej. Wykazano natomiast, że allel D występował istotnie rzadziej w grupie chorych na OBŚ niż 
w grupie kontrolnej (χ² = 4,25, p = 0,04). Ponadto, nosiciele allela I mieli trzykrotnie większe ryzyko wystąpienia OBŚ 
(HR = 2,748, 95% CI = 1,029–7,340, p < 0,05). 
Wnioski: Analiza polimorfizmu genu ACE może być przydatna w ocenie ryzyka wystąpienia OBŚ u osób klinicznie predyspo-
nowanych do rozwoju tej choroby.
Słowa kluczowe: polimorfizm ACE, obturacyjny bezdech w czasie snu, polisomnografia, PCR
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It needs to be emphasised that incidence of sleep 
apnoea syndrome was 41% in the subpopulation 
of patients with body mass index (BMI) over 
28 kg/m² [11].
Searching for causes of OSA is a multidirec-
tional process since many pathogenetic factors 
play a role in this entity. Among candidate genes 
which influence the risk of OSA there are gene 
polymorphisms which were observed to occur in 
diseases of similar pathogenesis to OSA. These 
include apolipoprotein E gene (APOEK), leptin and 
leptin receptor genes, proinflammatory cytokine 
genes including TNFA1, IL-6, IL-1, as well as β2- 
-adrenergic receptor gene (ADRB2) and angiotensin 
converting enzyme gene (ACE) [5].
It is widely accepted that the renin-angioten-
sin-aldosterone (RAA) system plays a major role 
in pathogenesis of cardiovascular diseases. The 
role of ACE activity in the occurrence of excessive 
body weight and abdominal obesity has been de-
monstrated. A key role in this system is played by 
peptidase, an enzyme that converts angiotensin I 
(AT I) into angiotensin II (AT II), the latter being 
a potent vasoconstrictor, promoting hyperplasia 
of smooth muscle in vascular walls and having 
prothrombotic activity. Furthermore, ACE cleaves 
bradykinin, which is a potent vasodilator and has 
an anticoagulative effect [12–14]. Angiotensin II 
has also antidiuretic effect, which is related to 
increased secretion of antidiuretic hormone (ADH) 
by the pituitary gland. In renal tubules AT II causes 
increased sodium absorption. The hormone also 
activates the adrenergic system [12].
Numerous polymorphisms were identified 
recently in gene coding elements of the renin- 
-angiotensin-aldosterone system. Correlations were 
also investigated between gene polymorphism 
and variegated expression of RAA genes. Polymor-
phisms of the angiotensin converting enzyme gene 
are attracting a great deal of researchers’ attention 
currently [12–14].
Gene coding for angiotensin I converting enzy-
me is located on the long arm of chromosome 17, 
in region 23 (17q23); it has 21 kilobase pairs and 
consists of 26 exons and 25 introns [12].
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In 1990, Rigat et al. [12] described for the first 
time polymorphism consisting of insertion or de-
letion of 287 base pairs within one of the noncoding 
parts of the ACE gene. This alteration can result in 
three genotypes which affect activity of angiotensin 
converting enzyme (II, DD, ID). The presence of 
D allele is believed to correlate with 60% higher ac-
tivity of serum ACE. Homozygotes DD have maximal 
ACE activity, heterozygotes ID have intermediate, 
and subjects with II genotype (lack of D allele) have 
the lowest serum ACE activity. Genotype DD of the 
ACE gene can therefore promote increased produc-
tion of angiotensin II and increased inactivation 
of bradykinin [12–14]. Significant correlation was 
found between polymorphism of the ACE gene and 
cardiovascular morbidity and mortality. Subjects 
with DD genotype of the ACE gene had increased 
risk of myocardial infarction, hypertrophy of the left 
ventricle, postinfarct myocardial remodelling, and 
idiopathic arterial hypertension [12–14].
The aim of the study was to assess the in-
cidence of insertion/deletion polymorphism of 
the ACE gene in patients with obstructive sleep 
apnoea and healthy subjects, as well as to analyse 
the influence of this polymorphism on the risk of 
OSA occurrence.
Material and methods
The study group consisted of 55 persons (46 
men and 9 women, aged 32–80 years, with median 
age of 57 years) hospitalised in the Department 
of Pneumonology, Oncology, and Allergology 
of the Medical University in Lublin. Included 
were patients referred to the department for OSA 
diagnostics as well as persons with previously 
diagnosed obstructive sleep apnoea. Sleep apnoea 
was assessed using Johns’ questionnaire, develo-
ped in Epworth, Australia (Epworth Sleepiness 
Scale, ESS). The questionnaire consists of eight 
questions concerning the patient’s daily activity. 
Interpretation of the answers may disclose mild 
(< 10 points), moderate (10–16 points), or marked 
somnolence during the daytime (> 16 points), 
which requires further diagnostics. 
Clinical somnographic investigations were 
performed using a Somnolab device (Weinmann, 
Germany) and Somnolab v1.31 SP1 software. 
Polysomnographic registration included parame-
ters concerning respiration (chest and abdominal 
movements), airflow in the upper respiratory tract, 
snoring, body position, heart rate, ECG chart, 
oximetry, and EEG chart. Only polysomnographic 
registration lasting for at least four hours was 
included in the study. Respiratory events were 
identified automatically and then manually verified 
by an investigator. Diagnostic criteria for sleep respi-
ratory aberrations were used as recommended by the 
American Academy of Sleep Medicine (AASM). The 
mean number of events (apnoea or hypopnoea) of at 
least five per one hour of registration (AHI ≥ 5) was 
one of the diagnostic criteria of apnoea syndrome. 
Sleep apnoea syndrome was diagnosed if AHI ≥ 5 co-
incided with marked somnolence or at least two signs 
or symptoms occurring during the daytime or during 
the night: feeling of choking during sleep, frequent 
waking up during sleep, feeling of unrest after sleep, 
feeling of tiredness, and decreased concentration 
and attention span. Diagnosis was also made when 
AHI ≥ 5 coincided with ESS ≥ 10 or when patients 
with no signs or symptoms had AHI ≥ 15 [1–4].
The apnoea-hypopnoea index (AHI) was also 
used for assessment of OSA severity, classified as 
mild for AHI 5–15 and falling asleep in situations 
that did not require much attention, moderate 
OSA at AHI 16–30 and patient falling asleep in 
situations requiring more attention, or severe OSA 
when AHI was > 30 and the patient was falling 
asleep during activities requiring maximal con-
centration [1–4].
Characteristics of patients with diagnosed 
OSA are presented in Table 1.
The control group consisted of 50 healthy 
persons aged 22–89 years (median age 60 years), in 
whom OSA was excluded using AASM criteria [1].
Each person from the study or control group 
completed a written informed consent and a veno-
us blood sample was used for genetic testing. Blood 
samples were taken into tubes containing ethyle-
nediaminetetraacetic acid (EDTA) and stored at 
–20ºC. Isolation of DNA from peripheral blood was 
performed using QIAamp® DNA Blood Mini kit 
(QIAGEN, USA). Assessment of DNA quality was 
performed using a BioPhotometer spectrophotome-
ter with cuvettes and UV/VIS filters (Eppendorf, 
Germany). Starter pairs of the following sequence 
were used for amplification of DNA fragments 
containing the investigated polymorphism site of 
the ACE gene (insertion/deletion): forward starter, 
5’ CTG GAG AGC CAC TCC CAT CCT TCT 3`; re-
verse starter (zero starter), and 5’ GAC GTG GCC 
ATC ACA TTC GTC AGA TC 3’. Polymerase chain 
reaction (PCR) was performed in the TPersonal 
thermocycler (Biometra, USA) with the following 
sequence: initial denaturation at 96ºC for 15 min, 
followed by 30 cycles of denaturation at 95ºC for 
30 s, hybridisation with starters at 61ºC for 30 s, 
and elongation at 72ºC for 2.5 minutes. After com-
pletion of all cycles, final elongation occurred at 
72ºC for 10 minutes. 
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The obtained PCR products were 190 base 
pairs (bp) for allele D or 480 bp for allele I. Se-
paration of DNA was performed on 2% agarose 
gel with ethidium bromide. After completion of 
electrophoresis, DNA bands were visualised using 
transiluminator under UV light. Figure 1 presents 
separated products of PCR reaction for ACE gene 
polymorphism. For homozygous genotypes II and 
DD, a single band was present, representing 480 bp 
product (lane 1, 8, 9, 10) or 190 bp product (lane 3, 
4, 11, 12, 15), respectively. Electrophoresis of PR 
products from heterozygous ID subjects produced 
two bands simultaneously: one of 480 bp and one 
of 190 bd (lanes 2, 5, 6, 7, 13, 14).
Distribution of respective genotypes and 
alleles in both investigated groups was asses-
sed according to the Hardy-Weinberg principle. 
Differences in incidence of respective alleles 
and genes between the groups were analysed 
using the χ2 test. The risk of OSA was assessed 
using the logistic regression test. Statistica 9.0 
software was used for analyses. For evaluation 
of deviation from the Hardy-Weinberg equili-
brium and of associations, a test available at the 
http://ihg.gsf.de/ihg/snps.html website was ap-
plied. Statistical significance level was adopted 
for p < 0.05.
Results
In the group of patients with OSA, II genoty-
pe was found in 17 persons (30.9%), ID genotype 
in 21 (38.2%), and DD genotype in 17 (30.9%). 
Incidences of respective genotypes in the control 
group were as follows: II genotype in 7 patients 
(14%), ID genotype in 25 (50%), and DD genotype 
in 18 (36%). The observed distribution of polymor-
phisms was concordant with the Hardy-Weinberg 
equilibrium.
Statistical analysis revealed no significant 
differences in incidence of respective ACE geno-
types between the study and the control group 
(Fig. 2). However, it should be emphasised that the 
II genotype was observed more often in patients 
with sleep apnoea than in the control group (χ2 = 
4.31; p = 0.116). Furthermore, D allele (both DD 
homozygotes and ID heterozygotes) was more often 
identified in healthy subjects (43 persons, 86%) 
than in patients with OSA (38 patients, 69.1%; χ² 
= 4.25, p = 0.04) (Fig. 3).
Subjects bearing the II genotype of the ACE gene 
had a significantly higher risk of developing OSA 
than subjects with ID genotype (HR [hazard ratio] = 
2.891, 95% CI [confidence interval] = 1.007–8.297; 
χ² = 4.03, p = 0.0447) and D allele carriers, includ-
ing subjects with ID or DD genotype (HR = 2.748, 
95% CI = 1.029–7.340; χ² = 4.25, p = 0.03932).
There were no significant differences in inci-
dence of respective ACE genotypes in patients with 
Figure 1. The representative electrophoregram of ACE gene I/D 
polymorphism. Lines by the order of the DNA marker: 1, 8, 10 — 
homozygous II; 2, 5, 6, 7, 13 and 14 — heterozygous ID; 3, 4, 11, 
12 and 15 — homozygous DD 
DD ID ID DD DD II II II ID ID ID DD DD ID II M
480pz
190pz
Table 1. Characteristics of patients with obstructive sleep 
apnoea/hypopnea syndrome
Assessed parameter Characteristics
Age (median value ± standard deviation) 57 ± 10.4 years
Sex
Men (n, %) 46 (83.6%)
Women (n, %) 9 (16.4%)
Cigarette smoking
Current smokers 15 (27.3%)
Past or non-smokers 40 (72.7%)
Body mass index (BMI, median value ± 
standard deviation)
33 ± 5.6
Concomitant diseases
Arterial hypertension 44 (80%)
Type 2 diabetes 11 (20%)
Chronic obstructive pulmonary disease 
(COPD)
18 (32.7%)
Coronary heart disease 7 (12.7%)
Metabolic syndrome 33 (60%)
Obesity 40 (72.7%)
OSA severity
 Mild 7 (12.7%)
 Moderate 17 (30.9%)
 Severe 31 (53.4%)
Apnoea-hypopnoea index (AHI, median value 
± standard deviation)
31 ± 19.1
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OSA and various concomitant diseases, including 
arterial hypertension, metabolic syndrome, and 
chronic obstructive pulmonary disease (COPD). 
Polymorphism of the ACE gene had no impact on 
OSA severity, as the median AHI value was simi-
lar in subgroups of different genotypes. The lack 
of significant correlation between the presence of 
I allele and OSA severity may be linked to a high 
number of patients with severe OSA in the studied 
population and few subjects with mild OSA.
Discussion
Most studies published to date concern 
the relationships between ACE activity and 
ACE polymorphism and risk of OSA complica-
tions, including arterial hypertension, as well 
as the occurrence of other diseases coexisting 
with OSA. The authors of the presented study 
performed genetic testing in order to assess the 
incidence of insertion/deletion polymorphism 
of the ACE gene in patients with OSA and in 
healthy control subjects presenting no respira-
tory disturbances during sleep. Distribution of 
II, ID, and DD genotypes did not differ signif-
icantly between the two groups, although the 
II genotype was slightly more common in sub-
jects with OSA compared to healthy subjects. 
These results are in accordance with data pub-
lished by other researchers.
Analysis of ACE polymorphism in Polish 
patients was previously performed by the group 
of Renata Rubinsztajn and Ryszarda Chazan in 
a population of 62 persons with OSA [15]. These 
authors reported a similar distribution of ACE pol-
ymorphism, with II genotype identified in 23.8% of 
patients, ID genotype in 47.6%, and DD genotype in 
28.6%. Patient stratification according to concom-
itant cardiovascular diseases and family tendency 
for OSA development did not significantly alter 
genotypic distribution.
One of the first reports concerning the inci-
dence of respective polymorphisms of the ACE 
gene in patients with OSA was published by Ogus 
et al.[17]. This study included a population of 101 
Turkish persons, including 64 patients with OSA 
and 37 subjects in the control group. Distribution 
of ACE genotypes was as follows: 27 patients had 
ID genotype, 27 had DD genotype, and 10 had II 
phenotype. There were no significant differences 
in genotypic distributions between the study and 
the control group. Barcelo et al. [17] reported 
similar observations based on analysis of the ACE 
genotype in 44 patients with OSA and 32 healthy 
subjects.
A study published by Lee et al. [18] seems 
to be the most reliable as it was performed in 
a population of 1,227 patients with OSA and 1,227 
healthy subjects. The authors did not observe 
any correlation between ACE gene polymorphism 
and risk of OSA development or disease severity. 
Risk of developing OSA was 0.92 for carriers of D 
allele (95% CI = 0.69–1.23). No significant corre-
lation between the presence of D allele and risk of 
OSA was observed after stratification according 
to ethnic origin or occurrence of other diseases, 
particularly arterial hypertension. However, the 
population investigated by Lee et al. was dominat-
ed by subjects of Asian ethnicity.
Contrary to the results reported by Lee et al., 
the authors of the presented study observed 
a significantly lower incidence of D allele of 
the ACE gene in patients with OSA compared to 
healthy subjects. Furthermore, the presence of 
I allele positively correlated with the risk of OSA 
development.
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Figure 2. Distribution of ACE genotypes in patients with OSAHS and 
in healthy persons
Figure 3. The frequency of allele I and allele D of ACE gene in 
patients with OSAHS and in healthy persons
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Ogus et al. did not observe significant dif-
ferences in the incidence of the respective ACE 
genotypes between patients with OSA and healthy 
persons in a Turkish population; however, the 
I allele was present more often in patients with 
sleep apnoea than in control subjects in their study 
(p = 0.02), and the risk of developing apnoea in 
group of I allele carriers was 2.41. These authors 
suggest that II and ID genotypes of the ACE gene 
may correlate with a higher risk of developing 
apnoea in the Turkish population [16].
However, the hypothesis of I allele increasing 
the risk of OSA development seems contradictory 
to publications concerning the relationships be-
tween ACE gene polymorphisms and modulation 
of skeletal muscle tone. It was observed that the 
endurance and strength of skeletal muscles during 
physical exercise in patients with COPD is higher 
in carriers of the I allele as compared to persons 
with DD genotype. This mechanism can possibly 
be protective against collapse and obturation of the 
upper respiratory tract in patients with OSA. This 
hypothesis warrants further investigation [19, 20].
As mentioned previously, most authors fo-
cused on correlations between ACE gene polymor-
phisms and the risk of developing cardiovascular 
diseases in patients with OSA. Koyama et al. [21] 
noted that I allele occurs more often in men with 
arterial hypertension and mild-to-moderate sleep 
apnoea but not with severe apnoea. These results 
led the authors to the hypothesis that the presence 
of I allele of the ACE gene in men suffering from 
arterial hypertension has a protective effect against 
severe OSA. This study included 266 Brazilian 
patients with OSA [16].
Zhang et al. [19] demonstrated that I allele of 
the ACE gene occurs more often in subjects with 
coexisting arterial hypertension and moderate-to- 
-severe OSA as compared to healthy persons. No such 
correlation was observed for I allele in patients 
with arterial hypertension and mild OSA versus 
control persons. The authors also reported that 
central obesity in patients with OSA and hyper-
tension correlate with the presence of the D allele 
in the ACE locus. However, polymorphisms of the 
ACE gene were not investigated in patients with 
OSA who did not have arterial hypertension. Fur-
thermore, the study included 174 patients of Asian 
origin, coming from the Han population, thereby 
impeding direct result comparison with studies 
concerning Caucasian subjects, even though the 
results seem to be similar.
The biggest study concerning correlations 
between ACE gene polymorphisms and risk of ar-
terial hypertension in patients with OSA enrolled 
1,100 mostly Caucasian persons (Wisconsin Sleep 
Cohort Study). Lin et al. [22] point to the fact that 
the risk of developing arterial hypertension by 
patients with mild-to-moderate OSA is correlated 
with presence of the D allele. These authors found 
the highest values of increased arterial pressure 
in subjects with DD genotype, and the lowest for 
the type II genotype. Interestingly, this correlation 
was most significant for patients with mild OSA. 
Similar results were reported by Boström et al. 
[23, 24], who compared 157 patients with OSA and 
arterial hypertension with 181 persons suffering 
from OSA but with no hypertension. Irrespective 
of OSA severity, the presence of the D allele in-
creased the risk of developing arterial hypertension 
in patients with sleep apnoea. These results are 
contradictory to those published by Patela et al. 
[24, 25], who studied 972 subjects during the 
Cleveland Family Study. Those authors reported 
a lower risk of arterial hypertension in carriers of 
the D allele in the ACE gene locus.
Such contradictory results of studies on the 
role of ACE polymorphism in development of 
arterial hypertension among patients suffering 
from OSA warrant further investigations and trials 
conducted in large patient populations.
Conclusions
1.  The incidence of the respective ACE genotypes 
in patients with OSA and healthy subjects 
was similar; however, the D allele of this gene 
was less often present in persons with signs 
of OSA. The presence of I allele increased the 
risk of developing OSA, which may suggest 
that polymorphism of the ACE gene influences 
genetic predisposition to this disease.
2.  Analysis of ACE polymorphism may be useful 
in the assessment of risk of OSA development 
in subjects with clinical signs suggesting pre-
disposition for the disease.
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